^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + JNK-IN-8 (JNK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-Jun N-terminal kinase inhibition
Published date:
06/23/2020
Excerpt:
Furthermore, a potent JNK inhibitor, JNK-IN-8, in combination with dasatinib markedly improved the survival of mice with BCR-ABL induced B-ALL, as compared to the treatment with dasatinib alone.